Japan approves Remdesivir to treat critically ill COVID-19 patients
Click here to read full article from source
Singapore, May 13 -- Gilead Sciences, Inc. has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury(R) (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States.
The approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases' global Phase 3 trial, Gilead's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from Gilead's compassionate use program, including patients in Japan.
To read the full article or to get the complete feed from this publication, please Contact Us